Wang et al. review preclinical and clinical data related to the importance of immune responses to radiotherapy-induced anti-tumor effects, as well as blockade of immune checkpoints PD-1/PD-L1 and/or CTLA-4 in combination with radiotherapy. The gene discussed is PDCD1; the disease is neoplasm.